Sort by

Send to

Choose Destination

Links from PubMed

Items: 5


Pains and Gains from China's Experiences with Emerging Epidemics: From SARS to H7N9.

Wei P, Cai Z, Hua J, Yu W, Chen J, Kang K, Qiu C, Ye L, Hu J, Ji K.

Biomed Res Int. 2016;2016:5717108. doi: 10.1155/2016/5717108. Epub 2016 Jul 20. Review.


Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.

Yang P, Duan Y, Zhang P, Li Z, Wang C, Dong M, Tang C, Xing L, Gu H, Zhao Z, Liu X, Zhang S, Wang X.

PLoS One. 2012;7(1):e30252. doi: 10.1371/journal.pone.0030252. Epub 2012 Jan 18.


Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice.

Meng S, Liu Z, Xu L, Li L, Mei S, Bao L, Deng W, Li L, Lei R, Xie L, Qin C, Zhang L.

PLoS One. 2011;6(5):e19863. doi: 10.1371/journal.pone.0019863. Epub 2011 May 20.


Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS.

Lindegardh N, Hanpithakpong W, Kamanikom B, Farrar J, Hien TT, Singhasivanon P, White NJ, Day NP.

Bioanalysis. 2011 Jan;3(2):157-65. doi: 10.4155/bio.10.189.


Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL.

Viruses. 2010 Feb 1;2(2):435-467.

Supplemental Content

Support Center